All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @pushupsnpumps on TikTok · 39s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @pushupsnpumps's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm in all of the night while the cat's meowing at you is a wonderful time to take your as I'm back
  2. 0:06Because again, I forgot to take it on Monday
  3. 0:09So here we are gonna prime the pen make sure a little bit comes out. Oh there we go
  4. 0:17That was really only like two clicks
  5. 0:22Pickles is trying to pickles not for you bro
  6. 0:29Pickles and there he's playing with my robe
  7. 0:36Okay, well done

GLP-1 drugs and Type 1 diabetes: what the evidence says

Pushupsnpumps

TikTok creator

607.5K viewsWatch on TikTok

Quick answer

The creator appears to be a Type 1 diabetic using an off-label GLP-1 receptor agonist (likely semaglutide based on the weekly pen-injection format), administering a delayed dose mid-week after missing their scheduled Monday injection. Semaglutide has a half-life of approximately seven days, and the FDA-approved prescribing information permits makeup dosing up to five days after the missed scheduled day. GLP-1 receptor agonists are not FDA-approved for Type 1 diabetes management, and their use in this population carries specific risks including hypoglycemia and, in combination with certain agents, elevated DKA risk that require individualized clinical supervision.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 drugs and Type 1 diabetes: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 drugs and Type 1 diabetes: what the evidence says" from Pushupsnpumps. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator appears to be a Type 1 diabetic using an off-label GLP-1 receptor agonist (likely semaglutide based on the weekly pen-injection format), administering a delayed dose mid-week after missing their scheduled Monday injection.

The reason this review is not generic is the source wording and the canonical claim label "glp1 pickles wanted to help diabetes t1dlookslikeme type1diabetes." In this clip, the useful excerpt is: "I'm in all of the night while the cat's meowing at you is a wonderful time to take your as I'm back Because again, I forgot to take it on Monday So here we are gonna prime the pen make sure a little bit comes out." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Semaglutide's half-life is approximately 7 days, which is why weekly dosing works and why a 2-day delay does not produce an abrupt pharmacological drop-off (Kristensen et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator appears to be a Type 1 diabetic using an off-label GLP-1 receptor agonist (likely semaglutide based on the weekly pen-injection format), administering a delayed dose mid-week after missing their scheduled Monday injection.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator appears to be a Type 1 diabetic using an off-label GLP-1 receptor agonist (likely semaglutide based on the weekly pen-injection format), administering a delayed dose mid-week after missing their scheduled Monday injection. Semaglutide has a half-life of approximately seven days, and the FDA-approved prescribing information permits makeup dosing up to five days after the missed scheduled day. GLP-1 receptor agonists are not FDA-approved for Type 1 diabetes management, and their use in this population carries specific risks including hypoglycemia and, in combination with certain agents, elevated DKA risk that require individualized clinical supervision.
  • FDA prescribing information for semaglutide (Ozempic/Wegovy) allows a missed weekly dose to be taken up to 5 days after the scheduled day; after that window, skip and resume the regular schedule.
  • Semaglutide's half-life is approximately 7 days, which is why weekly dosing works and why a 2-day delay does not produce an abrupt pharmacological drop-off (Kristensen et al., 2020, Clinical Pharmacokinetics).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • FDA prescribing information for semaglutide (Ozempic/Wegovy) allows a missed weekly dose to be taken up to 5 days after the scheduled day; after that window, skip and resume the regular schedule.
  • Semaglutide's half-life is approximately 7 days, which is why weekly dosing works and why a 2-day delay does not produce an abrupt pharmacological drop-off (Kristensen et al., 2020, Clinical Pharmacokinetics).
  • Pen priming before every injection is a manufacturer-recommended step that confirms needle patency and prevents air-pocket delivery errors that would reduce the actual dose received.
  • GLP-1 receptor agonists are not FDA-approved for Type 1 diabetes. Their use in T1D is off-label and requires individualized clinical oversight given mixed evidence and elevated risk profiles.
  • A 2023 meta-analysis (Shi et al., Diabetes Care) found that GLP-1 agonists in T1D patients produced modest HbA1c reductions but also raised hypoglycemia rates, particularly when combined with other glucose-lowering agents.
  • The American Diabetes Association's 2024 Standards of Care do not list GLP-1 agonists as a standard treatment option for Type 1 diabetes, distinguishing the T1D and T2D use cases significantly.
  • Time of day does not materially affect semaglutide pharmacokinetics; nighttime injection is neither contraindicated nor specifically recommended over other times.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @pushupsnpumps actually say?

Not much, honestly. This video is less a health claim and more a relatable slice of life: a Type 1 diabetic injecting what appears to be a GLP-1 medication late at night, having forgotten their Monday dose, while their cat Pickles stages a small rebellion. The creator mentions priming the pen, confirms "a little bit comes out," and notes the injection is being taken late due to forgetfulness. There are no sweeping medical claims here. That context matters for the fact-check.

The implicit message, though, is that taking a weekly injectable GLP-1 medication a few days late is fine, and that nighttime is an acceptable injection window. Those are the claims worth examining. The creator does not specify which GLP-1 they are using, but the pen-priming technique and weekly cadence suggest semaglutide (Ozempic or Wegovy) or a similar weekly injectable.

Does the science back this up?

On the "late dose" question, yes, with caveats. Semaglutide's half-life is approximately seven days, which is precisely why it is dosed weekly in the first place. Missing a day or two does not create a clinical cliff edge. The FDA prescribing information for Ozempic states that a missed dose can be administered up to five days after the scheduled day. So injecting on Wednesday instead of Monday is within that window.

On nighttime injection: there is no strong pharmacokinetic reason to avoid it. Semaglutide reaches peak plasma concentration roughly 24-48 hours post-injection regardless of time of day (Kristensen et al., 2020, Clinical Pharmacokinetics). Some patients prefer nighttime to blunt the initial nausea wave during sleep, a strategy that has anecdotal support but has not been rigorously tested in randomized trials. The pen-priming step the creator demonstrates is a legitimate and recommended safety practice to confirm needle patency before injection.

What did they get wrong (or right)?

The creator got the practical mechanics right. Priming the pen before injection is explicitly recommended in the manufacturer instructions for use for Ozempic and Wegovy. Confirming that "a little bit comes out" before injecting is exactly what you are supposed to do. That is not a small thing: delivering an air pocket instead of medication is a real user error that skews dosing.

What is worth flagging is the Type 1 diabetes context. GLP-1 receptor agonists are not FDA-approved as standalone treatments for Type 1 diabetes. Their use in T1D is off-label, and the evidence base is genuinely mixed. A 2023 meta-analysis (Shi et al., Diabetes Care) found modest HbA1c reductions in T1D patients using GLP-1 agonists, but also noted increased hypoglycemia risk and diabetic ketoacidosis concerns, particularly with SGLT-2 inhibitors used concurrently. The creator does not address any of this, which is understandable for a 30-second cat video, but viewers with T1D who see the hashtags and assume this is a straightforward recommendation should know the picture is more complicated.

What should you actually know?

If you use a weekly injectable GLP-1 medication and miss your scheduled day, do not panic and do not double-dose. The five-day makeup window for semaglutide is well-established. After that window, skip the missed dose and resume your regular schedule the following week. Always prime your pen. Always.

If you have Type 1 diabetes and are curious about GLP-1 medications, this is a conversation that genuinely requires your endocrinologist, not TikTok. The pharmacology is real, the potential benefits for weight and insulin sensitivity exist, but so do the risks. The American Diabetes Association's 2024 Standards of Care do not include GLP-1 agonists as a standard T1D treatment, which does not make them wrong for every T1D patient, but it does mean the decision needs individualized clinical oversight.

One more thing: the cat priming the injection for you is not a recognized technique and is not covered by any major diabetes organization's guidelines.

Bottom line

This video does not make harmful claims. It shows a real patient doing a real injection with correct technique. The implicit message that a late weekly dose is manageable is accurate. The T1D context adds complexity that the video does not address, and that gap is worth knowing about if you arrived here via the diabetes hashtags.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Pushupsnpumps · TikTok creator

607.5K views on this video

Pickles wanted to help. 🤷🏼‍♀️ #diabetes #t1dlookslikeme #type1diabetes #t1d #t1diabetes #type1diabetic #diabetesawareness #ozempic

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about fda prescribing information for semaglutide (ozempic/wegovy) allows a missed weekly?

FDA prescribing information for semaglutide (Ozempic/Wegovy) allows a missed weekly dose to be taken up to 5 days after the scheduled day; after that window, skip and resume the regular schedule.

What does the video say about semaglutide's half-life?

Semaglutide's half-life is approximately 7 days, which is why weekly dosing works and why a 2-day delay does not produce an abrupt pharmacological drop-off (Kristensen et al., 2020, Clinical Pharmacokinetics).

What does the video say about pen priming before every injection?

Pen priming before every injection is a manufacturer-recommended step that confirms needle patency and prevents air-pocket delivery errors that would reduce the actual dose received.

What does the video say about glp-1 receptor agonists?

GLP-1 receptor agonists are not FDA-approved for Type 1 diabetes. Their use in T1D is off-label and requires individualized clinical oversight given mixed evidence and elevated risk profiles.

What does the video say about a 2023 meta-analysis (shi et al., diabetes care) found?

A 2023 meta-analysis (Shi et al., Diabetes Care) found that GLP-1 agonists in T1D patients produced modest HbA1c reductions but also raised hypoglycemia rates, particularly when combined with other glucose-lowering agents.

What does the video say about the american diabetes association's 2024 standards of care do not?

The American Diabetes Association's 2024 Standards of Care do not list GLP-1 agonists as a standard treatment option for Type 1 diabetes, distinguishing the T1D and T2D use cases significantly.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Pushupsnpumps, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.